

Product Information Sheet for NR-12131

Polyclonal Anti-*Bacillus anthracis* Hypothetical Protein p5303 (Locus_Tag: BA_5699), (immunoglobulin G, Rabbit)

Catalog No. NR-12131

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor and Manufacturer:

Alison D. O'Brien, Ph.D., Chairperson, and James F. Sinclair, Ph.D., Laboratory Supervisor, Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA

Product Description:

Antibody Class: IgG

Polyclonal antiserum to hypothetical protein p5303 (locus_tag: <u>BA 5699</u>) of *Bacillus anthracis* (*B. anthracis*) was produced in rabbits and purified by protein G affinity chromatography.

Material Provided:

Each vial contains approximately 100 µg of NR-12131 in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-12131 was packaged aseptically in cryovials. The product is provided frozen on dry ice and should be stored at -80°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-12131 is specific to the p5303 hypothetical protein from *B. anthracis* by standard Western blot analysis and ELISA. NR-12131 binds to both native and denatured protein.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Polyclonal Anti-Bacillus anthracis Hypothetical Protein p5303 (Locus_Tag: BA_5699), (immunoglobulin G, Rabbit), NR-12131."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

 Cybulski, R. J., et al. "Recombinant Bacillus anthracis Spore Proteins Enhance Protection of Mice Primed with Suboptimal Amounts of Protective Antigen." <u>Vaccine</u> 26 (2008): 4927-4939. PubMed: 18657585.

ATCC[®] is a trademark of the American Type Culture Collection.

Biodefense and Emerging Infections Research Resources Repository

800-359-7370

Fax: 703-365-2898

E-mail: contact@beiresources.org